Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 5/20 | 0.40 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19836220 | 0.90 | TBK1 (0.41) | ULK1ULK2AURKAKDRAURKB | |
| SCHEMBL19836242 | 0.90 | TBK1 (0.41) | ULK1ULK2AURKAKDRAURKB | |
| SCHEMBL18995042 | 0.89 | BCL6 (0.42) | — | |
| SCHEMBL18994995 | 0.85 | CHEK1 (0.49) | ULK1ULK2AURKAKDRAURKB | |
| SCHEMBL18995069 | 0.81 | ULK1 (0.44) | ULK1ULK2AURKAKDRAURKB | |
| SCHEMBL19836663 | 0.79 | BCL6 (0.43) | — | |
| SCHEMBL19830190 | 0.77 | ULK1 (0.40) | ULK1ULK2CHEK1FLT3 | |
| SCHEMBL18994999 | 0.73 | ULK1 (0.43) | ULK1ULK2KDRCDK1 | |
| SCHEMBL15337710 | 0.69 | ULK1 (0.40) | ULK1ULK2CHEK1FLT3 | |
| SCHEMBL15337651 | 0.69 | ULK1 (0.40) | ULK1ULK2CHEK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | ULK1 282/4885ULK2 313/4885AURKA 2000/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | ULK1 282/4885ULK2 313/4885AURKA 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.